Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102131 | 0.94 | HSD17B2 (0.38) | HSD17B2PPARGPPARACASR | |
| SCHEMBL4102125 | 0.94 | HSD17B2 (0.38) | HSD17B2PPARGPPARACASR | |
| Hydrochloric Acid SCHEMBL4096494 | 0.93 | HSD17B2 (0.38) | HSD17B2PPARGPPARACASR | |
| Hydrochloric Acid SCHEMBL4096489 | 0.93 | HSD17B2 (0.38) | HSD17B2PPARGPPARACASR | |
| SCHEMBL1105788 | 0.88 | PPARG (0.37) | HSD17B2PPARGPPARACASRRAB9A | |
| SCHEMBL28769341 | 0.85 | HTR2A (0.40) | KMT2AMEN1PPARGCCR5MAPT | |
| SCHEMBL1095161 | 0.81 | CASR (0.43) | KMT2AMEN1CASR | |
| SCHEMBL4104904 | 0.80 | KMT2A (0.40) | KMT2AMEN1PPARGCCR5PPARA | |
| SCHEMBL4111691 | 0.80 | CASR (0.49) | CASR | |
| SCHEMBL4095414 | 0.80 | CASR (0.49) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | HSD17B2 753/4885KMT2A 3375/4885MEN1 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.